Global Cancer Vaccines Market - Size, Share Analysis, Growth Trends, and Forecasts spanning 2024-2033

The cancer vaccines market size has grown rapidly in recent years. It will grow from $7.22 billion in 2023 to $8.25 billion in 2024 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to rising incidence of cancer, increasing awareness of cancer vaccines, expanding range of approved cancer vaccines, growing evidence of the efficacy of cancer vaccines, government support for research and development.

The cancer vaccines market size is expected to see rapidly grown in the next few years. It will grow to $13.89 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to combination therapies with cancer vaccines, increased investment from pharmaceutical companies, emerging biomarkers, personalized vaccines, expanding vaccination programs. Major trends in the forecast period include advancements in immunology, adjuvant therapies, diversification of indications, patient access, collaborative research, neoantigen-based vaccines, therapeutic cancer vaccines.

Market Overview -
Cancer vaccines refer to cancer-treatment vaccinations and medications that aid the body in illness prevention and cancer treatment. They have the power to teach the immune system to recognize and eliminate dangerous microbes and cells.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3452&type=smp

Rising Cancer Cases Drive Demand For Cancer Vaccines
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer vaccines market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the cancer vaccine market over the coming years.

Competitive Landscape -
Major companies operating in the cancer vaccines market include GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Growing Demand For Preventive Cancer Vaccines Is Attracting Investment From Companies
Companies in the cancer vaccine market are increasingly investing in preventive or prophylactic vaccines for cancer prevention. Prophylactic vaccines are designed to build immunity in a patient. A prophylactic or preventative vaccine involves introducing antigens into a person's body. According to the World Health Organization, cervical cancer was reported as the second-most common cancer in women, with an estimated 84% of new cases worldwide. So far, there are 3 HPV vaccines currently available for the prophylaxis of cancer. Two of these will protect against both HPV 16 and HPV 18, which cause 70% of cervical cancer, and the third vaccine prevents 3 more oncogenic HPV types, which further cause 20% of cervical cancers. These three vaccines include Gardasil and Gardasil 9 by Merck and Cervarix by GSK.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Key Segments -
The cancer vaccines market covered in this report is segmented -
1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines
3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types
4) By End-User: Cancer Treatment Centers, Research Institutes

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.